Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
Category: #health  By Paroma Bhattacharya  Date: 2019-08-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar

Bio-Thera Solutions, a China based pharmaceutical company, has reportedly announced the start of dosing of its first batch of healthy volunteers in order to compare the safety and pharmacokinetics of BAT2506, proposed as a biosimilar of Simponi (golimumab), with EU-sourced Simponi in healthy volunteers.

According to Shengfeng Li, CEO at Bio- Thera, the phase 1 clinical trial for BAT2506, which is a biosimilar of Simponi, marks the fourth biosimilar that the company has advanced into clinical trials. Bio-Thera aims at facilitating safe and effective biosimilars to patients globally, he further added.

For the record, Bio- Thera Solutions is developing varied proposed biosimilars such as versions of Actemra/ RoActemra and Avastin which are being evaluated in global phase III clinical trials presently. Additionally, biosimilar versions of Stelara and Humira are also being developed.

Earlier in January 2019, the company had signed an agreement with Cipla to gain exclusive rights to market and distribute its bevacizumab biosimilar – BAT1706 used in the treatment of non-small cell lung cancer, in emerging markets.

The alliance was to leverage Cipla’s robust local presence, market capabilities and sales in the emerging markets. Bio-Thera on the other hand was responsible for the complete development and product registration process with the FDA and EMA along with commercial supply of BAT1706 from its manufacturing unit in China.

Reportedly, the Phase 1 BAT2506 study is expected to enroll 182 healthy volunteers, each of whom will be given a single subcutaneous dosage of either EU- sourced Simponi or BAT2506.

Bio-Thera Solutions is a leading biotechnology company which focuses on research and development of novel therapeutics in the diagnosis of cardiovascular diseases, autoimmune, cancer and other critical unmet diseases. Additionally, the firm develops biosimilars for prevailing, branded biologics to treat autoimmune diseases and cancer.

Furthermore, the company has multiple promising candidates in IND- enabling studies and early clinical trials aimed at innovative targets in autoimmune and immune-oncology diseases. 

 

Source Credits:

https://www.businesswire.com/news/home/20190814005245/en/Bio-Thera-Solutions-Initiates-Phase-Clinical-Trial-BAT2506



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...